NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.98
+5.51%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$4.96
From 52W high−65.10%
Volume48238.00
Market cap$22.80M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 23, 2026
Open
$4.96
From 52W high
−65.10%
Volume
48238.00
Market cap
$22.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
37.4
MomentumView details →
1D Return
+5.51%
YTD Return
−67.16%
SummaryUpdated Jun 1, 2026
NextCure, Inc. (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Beltsville, Maryland. The company went public in May 2019 and focuses on discovering and developing novel immunotherapies to treat cancer and other immune-related diseases. NextCure's approach centers on restoring normal immune function through targeted immunomodulation, representing a specialized segment within the broader cancer immunotherapy field.
Similar companies
Latest newsMore news →
NextCure, Inc. amended its lease agreement, accelerating the lease expiration to December 31, 2027, terminating rent obligations as of September 1, 2026, and paying a lump sum of $758,648 while forfeiting a $39,292.70 security deposit.51d agoXcellon Biologics acquires a GMP manufacturing facility from NextCure, becoming an end-to-end CRDMO for next-generation bioconjugates and complex biologics.75d agoAvere, an investee of Hansoh Pharmaceutical, merges into NextCure via a merger agreement, with Hansoh expected to hold more than 30% of the combined entity's equity.102d ago